Skip to main content
SpringerLink
Log in

Epidemiology and Health Economics of COPD Across Europe

A Critical Analysis

  • Review Article
  • Published:
Treatments in Respiratory Medicine

Abstract

COPD is a major cause of morbidity and mortality in Europe. The purpose of this literature review was to critically evaluate published data on COPD prevalence and the cost of COPD interventions in European countries. Selection of literature was based on article retrieval from a systematic literature search using PubMed and EMBASE. Only articles providing data in European countries published between January 1990 and March 2003 were included. European epidemiological (cross-sectional, cohort, case-control) and economic (cost-of-illness-, cost-minimization-, cost-effectiveness-, cost-benefit-, cost-utility-analysis) studies were included.

Of 74 retrieved epidemiologic studies, only seven (9%) fulfilled the inclusion criteria. In the selected literature, COPD prevalence ranged from 3% among Finnish women to 57% among Italian men and women, 45 years and older. Of 56 economic studies, 24 satisfied entry criteria. Results from the final cost-of-illness studies indicated that hospital care and medication represented the major portion of costs associated with COPD. In a survey conducted in 1998/99, annual direct expenditures for COPD treatment per patient in Europe ranged from €530 in France to €3238 in Spain. There was a differential increase in COPD prevalence predominantly related to an aging patient population, with a high incidence of exposure to cigarette smoke. Data also showed differences in the economic impact of COPD in Europe based on the proportion of patients with severe COPD, frequency of exacerbations, and number of hospitalizations. Overall, results of this review demonstrated the need for global epidemiologic and economic studies to allow for more uniform guidelines for the prevention and cost-effective treatment of patients with COPD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000; 55(9): 789–94

    Article  PubMed  CAS  Google Scholar 

  2. Dagli E. The statement of the European Respiratory Society for the WHO Framework Convention on Tobacco Control public hearings session. European Respiratory Society [online]. Available from URL: http://www3.who.int/whosis/fctc/Submissions/F1350132.pdf [Accessed 2003 Dec 18]

  3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349(9061): 1269–76

    Article  PubMed  CAS  Google Scholar 

  4. Burney P, Suissa S, Soriano JB, et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J Suppl 2003; 43: 1S–44S

    PubMed  CAS  Google Scholar 

  5. Konietzko N, Fabel H. Weissbuch Lunge 2000; Defizite, Zukunftsperspektiven, Forschungsansätze; Die Lunge und ihre Erkrankungen: Zur Lage und Zukunft der Pneumologie in Deutschland. Stuttgart: Georg Thieme Verlag, 2000

    Google Scholar 

  6. Rutten van-Molken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from the Netherlands. Pharmacoeconomics 2001; 19 Suppl. 2: 1–6

    Article  Google Scholar 

  7. Graf von der Schulenburg J-M, Hoffman C. Review of European guidelines for economic evaluation of medical technologies and Pharmaceuticals. HEPAC 2000; (1): 2-8

  8. Evaluation of impairment/disability secondary to respiratory disorders. American Thoracic Society. Am Rev Respir Dis 1986; 133 (6): 1205–9

    Google Scholar 

  9. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52 Suppl. 5: S1–28

    Google Scholar 

  10. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8(8): 1398–420

    CAS  Google Scholar 

  11. National Heart, Lung, and Blood Institute and World Health Organization and the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [online]. Available from URL: http://www.goldcopd.com [Accessed 2003 Dec 18]

  12. Isoaho R, Puolijoki H, Huhti E, et al. Prevalence of chronic obstructive pulmonary disease in elderly Finns. Respir Med 1994; 88(8): 571–80

    Article  PubMed  CAS  Google Scholar 

  13. Viegi G, Pedreschi M, Pistelli F, et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000; 117(5 Suppl. 2): 339S–45S

    Article  PubMed  CAS  Google Scholar 

  14. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28(4): 717–22

    Article  PubMed  CAS  Google Scholar 

  15. Bakke PS, Baste V, Hanoa R, et al. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991; 46(12): 863–70

    Article  PubMed  CAS  Google Scholar 

  16. Montnemery P, Adelroth E, Heuman K, et al. Prevalence of obstructive lung diseases and respiratory symptoms in southern Sweden. Respir Med 1998; 92(12): 1337–45

    Article  PubMed  CAS  Google Scholar 

  17. Donato F, Pasini GF, Buizza MA, et al. Tobacco smoking, occupational exposure and chronic respiratory disease in an Italian industrial area. Monaldi Arch Chest Dis 2000; 55(3): 194–200

    PubMed  CAS  Google Scholar 

  18. Pena VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118(4): 981–9

    Article  PubMed  CAS  Google Scholar 

  19. Radon K, Busching K, Heinrich J, et al. Passive smoking exposure: a risk factor for chronic bronchitis and asthma in adults? Chest 2002; 122(3): 1086–90

    Article  PubMed  Google Scholar 

  20. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997; 10(5): 1064–71

    Article  PubMed  CAS  Google Scholar 

  21. Prescott E, Vestbo J. Socioeconomic status and chronic obstructive pulmonary disease. Thorax 1999; 54(8): 737–41

    Article  PubMed  CAS  Google Scholar 

  22. Watson L, Margetts B, Howarth P, et al. The association between diet and chronic obstructive pulmonary disease in subjects selected from general practice. Eur Respir J 2002; 20(2): 313–8

    Article  PubMed  CAS  Google Scholar 

  23. Tabak C, Smit HA, Rasanen L, et al. Alcohol consumption in relation to 20-year COPD mortality and pulmonary function in middle-aged men from three European countries. Epidemiology 2001; 12(2): 239–45

    Article  PubMed  CAS  Google Scholar 

  24. Seersholm N, Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency. Thorax 1998; 53(4): 265–8

    Article  PubMed  CAS  Google Scholar 

  25. Hospers JJ, Postma DS, Rijcken B, et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356(9238): 1313–7

    Article  PubMed  CAS  Google Scholar 

  26. McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med 2001; 164 (8 Pt 1): 1419–24

    PubMed  CAS  Google Scholar 

  27. Gold DR, Wang X, Wypij D, et al. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335(13): 931–7

    Article  PubMed  CAS  Google Scholar 

  28. Jacobson L, Hertzman P, Lofdahl CG, et al. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000; 94(3): 247–55

    Article  PubMed  CAS  Google Scholar 

  29. Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest 2002; 122(6): 1994–2002

    Article  PubMed  Google Scholar 

  30. Britton M. The burden of COPD in the UK: results from the confronting COPD survey. Respir Med 2003; 97: 71–9

    Article  Google Scholar 

  31. Rutten-van Molken MP, Postma MJ, Joore MA, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir Med 1999; 93(11): 779–87

    Article  PubMed  CAS  Google Scholar 

  32. Wouters EF. The burden of COPD in the Netherlands: result from the confronting COPD survey. Respir Med 2003; 97: 51–9

    Article  Google Scholar 

  33. Ruff LK, Volmer T, Nowak D, et al. The economic impact of smoking in Germany. Eur Respir J 2000; 16(3): 385–90

    Article  PubMed  CAS  Google Scholar 

  34. Piperno D, Huchon G, Pribil C, et al. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003; 97 Suppl. C: S33–42

    Article  PubMed  Google Scholar 

  35. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97: 43–50

    Article  Google Scholar 

  36. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003; 97: 61–9

    Article  Google Scholar 

  37. Dal Negro R, Berto P, Tognella S, et al. Cost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis 2002; 57(1): 3–9

    Google Scholar 

  38. Miravitlles M, Murio C, Guerrero T, et al. Costs of chronic bronchitis and COPD: A 1-year follow-up study. Chest 2003; 123(3): 784–91

    Article  PubMed  Google Scholar 

  39. Guest JF. The annual cost of chronic obstructive pulmonary disease to the UK’s national health service. Dis Manage Health Outcomes 1999; 5: 93–100

    Article  Google Scholar 

  40. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9): 700–8

    Article  PubMed  CAS  Google Scholar 

  41. Riecke K, Eller J, Gericke C, et al. Inpatient treatment costs of exacerbated chronic obstructive lung disease [in German]. Pneumologie 1999; 53(4): 199–206

    PubMed  CAS  Google Scholar 

  42. Pechevis M, Fagnani F, Brin S, et al. Recurrent respiratory infections in patients with chronic obstructive bronchitis: medical treatment and costs [in French]. Rev Mal Respir 1996; 13(5): 507–12

    PubMed  CAS  Google Scholar 

  43. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121(5): 1449–55

    Article  PubMed  Google Scholar 

  44. Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med 2003; 97(1): 20–6

    Article  PubMed  CAS  Google Scholar 

  45. Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med 2003; 97: 212–20

    Article  PubMed  CAS  Google Scholar 

  46. Skwarska E, Cohen G, Skwarski KM, et al. Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55(11): 907–12

    Article  PubMed  CAS  Google Scholar 

  47. Hernandez C, Casas A, Escarrabill J, et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Respir J 2003; 21(1): 58–67

    Article  PubMed  CAS  Google Scholar 

  48. Pelletier-Fleury N, Lanoe JL, Fleury B, et al. Cost-effectiveness study of 2 long-term home oxygen therapy management systems [in French]. Rev Epidemiol Sante Publique 1997; 45(1): 53–63

    PubMed  CAS  Google Scholar 

  49. Farrero E, Escarrabill J, Prats E, et al. Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy. Chest 2001; 119(2): 364–9

    Article  PubMed  CAS  Google Scholar 

  50. Gallefoss F, Bakke PS. Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD: a 1-year follow-up randomized, controlled trial. Respir Med 2002; 96(6): 424–31

    Article  PubMed  Google Scholar 

  51. Griffiths TL, Phillips CJ, Davies S, et al. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001; 56(10): 779–84

    Article  PubMed  CAS  Google Scholar 

  52. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123(5): 1684–92

    Article  PubMed  CAS  Google Scholar 

  53. Celli BR, Halbert RJ, Isonaka S, et al. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22(2): 268–73

    Article  PubMed  CAS  Google Scholar 

  54. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir Med 2002; 96 Suppl. C: S3–10

    Article  PubMed  Google Scholar 

  55. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124(2): 459–67

    Article  PubMed  Google Scholar 

  56. Viegi G, Scognamiglio A, Baldacci S, et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68(1): 4–19

    Article  PubMed  CAS  Google Scholar 

  57. Pascual-Pape T, Badia JR, Marrades RM, et al. Results of a preventive program and assisted hospital discharge for COPD exacerbation: a feasibility study [in French]. Med Clin (Barc) 2003; 120(11): 408–11

    Article  Google Scholar 

  58. Murphy NM, Byrne CC, O’Neill SJ, et al. An outreach programme for patients with an exacerbation of chronic obstructive pulmonary disease. Ir Med J 2003; 96(5): 137–40

    PubMed  CAS  Google Scholar 

  59. Barbieri M, Drummond MF. Conflict of interest in industry-sponsored economic evaluations: real or imagined? Curr Oncol Rep 2001; 3(5): 410–3

    Article  PubMed  CAS  Google Scholar 

  60. National Institutes of Health, Lung, and Blood Institute. GOLD Workshop Update 2003. Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [online]. Available from URL: http://www.goldcopd.com [Accessed 2001 Apr 30]

Download references

Acknowledgments

The authors thank Professor Leonardo M. Fabbri for his support in revising the manuscript. This review was supported by a grant from ALTANA Pharma AG.

Dennis Nowak is an advisor to GlaxoSmithKline, Altana Pharma, Boehringer, and Novartis.

Author information

Authors and Affiliations

  1. Institute and Outpatient Clinic for Occupational and Environmental Medicine, Ludwig-Maximilians-University, Munich, Germany

    Dennis Nowak

  2. Medical Economics Research Group (MERG), Paul-Gerhardt-Allee 42, Munich, D-81245, Germany

    Karin Berger, Barbara Lippert & Katharina Kilgert

  3. ALTANA Pharma AG, Konstanz, Germany

    Manfred Caeser & Ruediger Sandtmann

Authors
  1. Dennis Nowak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karin Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Lippert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katharina Kilgert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manfred Caeser
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ruediger Sandtmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karin Berger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nowak, D., Berger, K., Lippert, B. et al. Epidemiology and Health Economics of COPD Across Europe. Treat Respir Med 4, 381–395 (2005). https://doi.org/10.2165/00151829-200504060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200504060-00003

Keywords

Search

Navigation